Bayer’s chief executive is considering farming out certain drug research activities to cut costs amid slower growth at its pharmaceuticals division, the German company’s works council said on Monday.
The works council cited CEO Werner Baumann as he spoke to staff at a gathering at the group’s Leverkusen headquarters on Sept 28. Reuters reported last month that considerable restructuring efforts at drug research and development, including outsourcing, were underway.
“Werner Baumann spoke about the prospect of weaker growth at the pharmaceutical business and mentioned considerations that some expenditures on pharma research could be outsourced,” the works council said in a statement.
A person familiar with the company told Reuters last month that Bayer, which bought Monsanto for $63 billion this year, is considering job cuts and outsourcing as part of a wide-ranging review of drug research and development that will last until at least November.
The savings that Bayer – the inventor of aspirin and maker of Yasmin birth control pills – could make as part of the overhaul would give it financial wiggle room as it competes with larger rivals to buy the right to promising treatments from biotech firms.
Revenues from the drug unit’s top products, blood thinner Xarelto and eye drug Eylea, will peak over the next six years.
A Bayer spokesman said Baumann’s remarks were in reference to plans to intensify external collaborations, which had previously been communicated.
The works council said it wanted more information and demanded wider-ranging job guarantees, beyond a pact that was previously agreed with the company.
By Patricia Weiss
Novo Nordisk has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has provided a positive opinion for the company’s Sogroya therapy. The once-weekly treatment – also known as somapacitan – is for the replacement of endogenous growth hormone (GH) in aged children three years and older.
Medtronic is set to acquire EOFlow, the South Korea-based maker of an insulin patch pump. In its announcement of the deal Thursday, Medtronic suggested that integrating the tubeless device with its own continuous glucose monitors and meal-detection algorithm could create a new closed-loop system for largely hands-off diabetes management.
Apnimed started the year by bagging nearly $80 million in extended series C funds and the momentum has kept up, with the sleep-apnea-focused biotech nailing its goals in a phase 2 study. “For those who cannot tolerate current treatments, AD109 has the potential to be a convenient, oral pill that could improve people’s quality of life both at night and during the day.”